Drug Eluting Balloons (DEBs)

Global Drug Eluting Balloons (DEBs) Market to Reach US$3.4 Billion by 2030

The global market for Drug Eluting Balloons (DEBs) estimated at US$1.8 Billion in the year 2024, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 11.5% over the analysis period 2024-2030. Peripheral DEBs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Coronary DEBs segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$486.8 Million While China is Forecast to Grow at 11.0% CAGR

The Drug Eluting Balloons (DEBs) market in the U.S. is estimated at US$486.8 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$534.7 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.6% and 9.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Drug Eluting Balloons (DEBs) Market - Key Trends and Drivers Summarized

What Are Drug Eluting Balloons (DEBs) and Why Are They Revolutionary in Medical Treatments?

Drug Eluting Balloons (DEBs) are an innovative class of medical devices used primarily in the treatment of peripheral and coronary artery diseases. These balloons are coated with medication that is delivered directly to the artery`s wall during the angioplasty procedure. Unlike traditional balloon angioplasty that mechanically opens the artery without delivering any therapeutic agents, DEBs provide a dual function: they not only expand the artery to alleviate blockages but also deliver a drug locally to inhibit restenosis (the re-narrowing of the artery). The primary medications used on DEBs are antiproliferative drugs, which help prevent the growth of scar tissue, thus maintaining arterial patency over time and improving patient outcomes significantly.

How Do Drug Eluting Balloons Enhance Clinical Efficacy Compared to Conventional Methods?

The key advantage of drug eluting balloons over traditional treatments lies in their ability to minimize the risk of restenosis and eliminate the need for permanent implants like stents. This is particularly beneficial for patients who may be prone to stent thrombosis or those who have difficulties with long-term antiplatelet therapy. DEBs release medication that inhibits cell proliferation directly at the site of arterial injury caused by the balloon dilation, providing targeted therapeutic action while reducing systemic side effects. This local delivery system ensures a high local drug concentration immediately after the procedure, offering a more effective treatment compared to systemic drug delivery methods.

What Challenges and Innovations Shape the Future of DEBs?

Despite their benefits, the development and usage of DEBs face several challenges. The primary concern is the precision of drug coating and its transfer efficiency during the procedure. Innovations in balloon technology focus on improving the homogeneity and adherence of the drug coating, ensuring that the correct dosage is delivered directly to the arterial wall. Researchers are also exploring biodegradable polymers that can control drug release rates to optimize healing. Regulatory hurdles represent another significant challenge, as the combination of device and drug into a single product requires extensive validation to meet safety and efficacy standards set by health authorities globally.

What Drives the Growth in the Drug Eluting Balloons Market?

The growth in the drug eluting balloons market is driven by several factors, starting with the rising prevalence of cardiovascular diseases worldwide, which increases the demand for effective, minimally invasive treatment options. Advances in materials science have enabled the development of more efficient drug delivery systems on DEBs, enhancing their appeal to interventional cardiologists. The growing body of clinical evidence supporting the efficacy and safety of DEBs compared to conventional therapies is also compelling more healthcare providers to adopt this technology. Furthermore, the desire for treatments that reduce hospital stay durations and improve patient quality of life post-procedure boosts the adoption of DEBs. As healthcare systems increasingly focus on cost-effectiveness and better patient outcomes, the market for drug eluting balloons is expected to continue expanding, fueled by technological innovations and strategic collaborations among key industry players.

SCOPE OF STUDY:

The report analyzes the Drug Eluting Balloons (DEBs) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Peripheral, Coronary); End-Use (Hospitals, Cath Labs, Ambulatory Surgery Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Acrostak Int. Distr. Sarl
• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Cardionovum GmbH
• Cook Medical, Inc.
• Eurocor GmbH
• Medtronic PLC
• Spectranetics Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.